Outcomes Tables Categorized by Key Question and Outcome

Evidence Table 59. KQ1—Dichotomous data—Mortality

| **Author Year****Study design** | **Definition of outcome (if relevant)** | **CHD risk category** | **CVD drug (dose mg/d)** | **Group 1: Supplement name (dose g/d)** | **N1** | **N1 with event** | **Group 2: Name** | **N2** | **N2 with event** | **Estimates of Group Differences** | **Additional comments** | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ***All cause mortality*** |  |  |  |  |  |  |  |  |  |  |  |  |
| Sconce 2007 61Parallel | N/A | Unclear | Warfarin (3.3-4.4) | Vitamin K (0.15) | 35 | 0 | Placebo | 33 | 1 |  |  | Medium |
| Eritsland 1996 21Parallel | N/A | High  | ASA (300) | Fish/marine oils (4) | 143 | 5 | No treatment | 148 | 4 |  |  | Medium |
| Eritsland 1996 21Parallel | N/A | High | Warfarin (NR) | Fish/marine oils (4) | 174 | 3 | No treatment | 145 | 2 |  |  | Medium |
| Garg 1995 24Parallel | N/A | High | ASA and/or pentoxiphylline (NR) | *Ginkgo biloba* (0.16) | 29 | 0 | Placebo | 26 | 0 |  |  | High |
| Roth 2009 60Parallel | N/A | Unclear | Fenofibrates (130) | Omega-3 (EPA, DHA or both) (4) | 84 | 0 | Placebo | 83 | 0 |  |  | Medium |
| Di Spirito 2008 19Cross-over | N/A | Low (healthy) | Atorvastatin (80) | Omega-3 (EPA, DHA or both) (4) | 50 | 0 | No treatment | 50 | 0 |  |  | Medium |

Evidence Table 59. KQ1—Dichotomous data—Mortality

| **Author Year****Study design** | **Definition of outcome (if relevant)** | **CHD risk category** | **CVD drug (dose mg/d)** | **Group 1: Supplement name (dose g/d)** | **N1** | **N1 with event** | **Group 2: Name** | **N2** | **N2 with event** | **Estimates of Group Differences** | **Additional comments** | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Watson 1999 66Cross-over | N/A | High | Mixed: ACE inhibitors + furosemide, digoxin, hydralazine and/or nitrates (NR) | Coenzyme Q10 (0.1) | 30 | 0 | Placebo | 30 | 1 |  |  | Medium |
| ***Vascular death –*** *no outcome data* |  |  |  |  |  |  |  |  |  |  |  |  |
| ***Specific vascular death*** – no outcome data |  |  |  |  |  |  |  |  |  |  |  |  |